bindarit has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, XC; Hu, HL; Lai, PL; Wang, XJ; Yang, JC; Yuan, SG; Zhou, RP | 1 |
| Chen, W; Foo, SS; Forwood, MR; Herrero, LJ; Hueston, L; Lulla, A; Mahalingam, S; Merits, A; Sims, NA; Taylor, A; Walsh, NC | 1 |
2 other study(ies) available for bindarit and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bindarit Reduces Bone Loss in Ovariectomized Mice by Inhibiting CCL2 and CCL7 Expression via the NF-κB Signaling Pathway.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Chemokine CCL2; Chemokine CCL7; Cytokines; Female; Humans; I-kappa B Kinase; Indazoles; Mice; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Ovariectomy; Propionates; RNA, Messenger; Signal Transduction; X-Ray Microtomography | 2022 |
Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.
Topics: Adult; Aged; Animals; Bone Density Conservation Agents; Bone Resorption; Chemokine CCL2; Chikungunya Fever; Disease Models, Animal; Female; Humans; Indazoles; Male; Mice, Inbred C57BL; Middle Aged; Propionates | 2015 |